image
Healthcare - Medical - Devices - NASDAQ - US
$ 0.2897
-21.1 %
$ 1.79 M
Market Cap
0.02
P/E
1. INTRINSIC VALUE

Tivic Health Systems Inc. operates as a bioelectronic device company that delivers non-invasive neuromodulation products for the treatment of inflammatory conditions. Its primary product is ClearUP, is a medical device intended to relieve sinus and nasal inflammation. The company sells its products on direct-to-consumer channel through its own websites; and platforms, such as Amazon.com and Walmart.com, as well as to U.S. online retailers, including BestBuy.com and FSAStore.com. Tivic Health Systems, Inc. was incorporated in 2016 and is headquartered in Hayward, California.[ Read More ]

The intrinsic value of one TIVC stock under the base case scenario is HIDDEN Compared to the current market price of 0.29 USD, Tivic Health Systems, Inc. is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart TIVC

image
FINANCIALS
1.18 M REVENUE
-36.09%
-8.24 M OPERATING INCOME
18.35%
-8.24 M NET INCOME
18.34%
-8.51 M OPERATING CASH FLOW
4.57%
-118 K INVESTING CASH FLOW
-972.73%
8.51 M FINANCING CASH FLOW
1711.17%
126 K REVENUE
-10.00%
-1.43 M OPERATING INCOME
-18.66%
-1.43 M NET INCOME
-13.03%
-1.41 M OPERATING CASH FLOW
-9.32%
0 INVESTING CASH FLOW
0.00%
-97 K FINANCING CASH FLOW
-2.93%
Balance Sheet Decomposition Tivic Health Systems, Inc.
image
Current Assets 4.65 M
Cash & Short-Term Investments 3.4 M
Receivables 174 K
Other Current Assets 1.08 M
Non-Current Assets 505 K
Long-Term Investments 0
PP&E 471 K
Other Non-Current Assets 34 K
Current Liabilities 1.4 M
Accounts Payable 713 K
Short-Term Debt 386 K
Other Current Liabilities 302 K
Non-Current Liabilities 176 K
Long-Term Debt 176 K
Other Non-Current Liabilities 0
EFFICIENCY
Earnings Waterfall Tivic Health Systems, Inc.
image
Revenue 1.18 M
Cost Of Revenue 889 K
Gross Profit 287 K
Operating Expenses 8.53 M
Operating Income -8.24 M
Other Expenses -999
Net Income -8.24 M
RATIOS
24.40% GROSS MARGIN
24.40%
-701.11% OPERATING MARGIN
-701.11%
-701.02% NET MARGIN
-701.02%
-230.28% ROE
-230.28%
-159.86% ROA
-159.86%
-218.53% ROIC
-218.53%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Tivic Health Systems, Inc.
image
Net Income -8.24 M
Depreciation & Amortization 182 K
Capital Expenditures -118 K
Stock-Based Compensation 271 K
Change in Working Capital -752 K
Others -118 K
Free Cash Flow -8.63 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Tivic Health Systems, Inc.
image
TIVC has no price targets from Wall Street.
4. DIVIDEND ANALYSIS
0.00% DIVIDEND YIELD
0 USD DIVIDEND PER SHARE
5. COMPETITION
6. Ownership
Insider Ownership Tivic Health Systems, Inc.
image
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
Date Value Insider Amount Avg Price
7. News
Tivic Reports Third Quarter 2024 Financial Results and Provides Business Update FREMONT, Calif.--(BUSINESS WIRE)--Tivic Health® Systems, Inc. (Nasdaq: TIVC), a health tech company that develops and commercializes bioelectronic medicine, today announced third quarter and nine-months ended September, 30, 2024 financial results and discussed growth strategies based on its novel, patent-pending vagus nerve stimulation (VNS) science and device technology. “This quarter we made significant progress on each of the three prongs of our strategy for delivering shareholder value," st. businesswire.com - 2 days ago
Tivic Health Systems, Inc. (TIVC) Q3 2024 Earnings Call Transcript Tivic Health Systems, Inc. (NASDAQ:TIVC ) Q3 2024 Earnings Conference Call November 14, 2024 4:30 PM ET Company Participants Jennifer Ernst - Chief Executive Officer Operator Welcome to Tivic Health Systems' Third Quarter 2024 Financial Results and Operational Update Conference Call. This call has been pre-recorded and questions you have submitted in advance will be answered following the prepared remarks. seekingalpha.com - 2 days ago
Enrollment Complete in Tivic Health Optimization Study for its Non-Invasive Vagus Nerve Stimulation Device FREMONT, Calif.--(BUSINESS WIRE)--Tivic Health® Systems, Inc. (Nasdaq: TIVC), a health tech company developing and commercializing bioelectronic medicine, announced today that full enrollment has been completed in the optimization study for Tivic Health's patent pending, non-invasive vagus nerve stimulation (VNS) device. The study is being conducted by The Feinstein Institute of Bioelectronic Medicine. The objective of the study is to identify device parameters that optimally influence autonomi. businesswire.com - 2 days ago
Tivic Health Systems, Inc. to Report Third Quarter 2024 Financial Results on November 14 FREMONT, Calif.--(BUSINESS WIRE)--Tivic Health® Systems, Inc. (Nasdaq: TIVC), a health tech company that develops and commercializes bioelectronic medicine, today announced it will report financial results on Thursday, November 14 after market close. The release will be followed by a pre-recorded conference call and webcast at 1:30 p.m. PST / 4:30 p.m. EST. Shareholders, interested parties, and prospective investors are invited to join via dial in or webcast. The company invites questions to be. businesswire.com - 1 week ago
Tivic Health CEO Jennifer Ernst to Present at New York BioFuture 2024 SAN FRANCISCO--(BUSINESS WIRE)--Tivic Health® Systems, Inc. (Nasdaq: TIVC), a health tech company developing and commercializing bioelectronic medicine, announced today that CEO Jennifer Ernst will presenting at the upcoming BioFuture 2024 Conference in New York, October 28-30. Ms. Ernst's presentation, Tuesday, October 29 at 2:30 p.m. EDT, will focus on the company's advances in bioelectronic medicine, including its recently released data on a new approach to vagus nerve stimulation. “This yea. businesswire.com - 3 weeks ago
Tivic Health Accelerates VNS Commercial Strategy Development SAN FRANCISCO--(BUSINESS WIRE)--Tivic Health® Systems, Inc. (“Tivic Health”, Nasdaq: TIVC), a health tech company that develops and commercializes bioelectronic medicine, today announced it has partnered with Fletcher Spaght (“FSI”), a leading healthcare growth strategy firm, to accelerate development of its commercial strategy for non-invasive cervical vagus nerve stimulation (“ncVNS”). Polaris Market Research estimates the global vagus nerve stimulation market will grow from $8.59 billion in. businesswire.com - 1 month ago
Tivic Health Systems, Inc. (TIVC) Q2 2024 Earnings Call Transcript Tivic Health Systems, Inc. (NASDAQ:TIVC ) Q2 2024 Earnings Conference Call August 14, 2024 4:30 PM ET Company Participants Jennifer Ernst - Chief Executive Officer Kimberly Bambach - Interim Chief Financial Officer Blake Gurfein - Chief Scientific Officer Operator Welcome to the Tivic Health Systems' Second Quarter 2024 Financial Results and Shareholder Update Conference Call. All participants will be in listen-only mode. seekingalpha.com - 3 months ago
Tivic Reports Second Quarter 2024 Financial Results SAN FRANCISCO--(BUSINESS WIRE)--Tivic Health® Systems, Inc. (“Tivic”, Nasdaq: TIVC), a health tech company that develops and commercializes bioelectronic medicine, today announced its second quarter 2024 financial results and discussed growth strategies based on its investments in vagus nerve stimulation ("VNS"). “This quarter is the start of a potentially transformational period for Tivic. We announced the results of our successful Phase 1 trial of a new approach to non-invasive vagus nerve st. businesswire.com - 3 months ago
Tivic Health to Report Q2 2024 Financial Results and Corporate Update on August 14th Via Conference Call and Webcast SAN FRANCISCO--(BUSINESS WIRE)--Tivic Health® Systems, Inc. (“Tivic Health”, Nasdaq: TIVC), a health tech company that develops and commercializes bioelectronic medicine, today announced that it will report its Q2 2024 financial results and a corporate update via pre-recorded conference call and webcast on Wednesday, August 14 at 1:30 PM PT / 4:30 PM ET. Current shareholders, interested individuals and future investors are encouraged to join the webcast to hear the company executives provide a. businesswire.com - 3 months ago
Tivic Health Systems (TIVC) Stock Pops Another 39% Tivic Health Systems (NASDAQ: TIVC ) stock is on the rise Monday as the company's shares have been volatile the last few days of trading. Initially, shares of TIVC stock were pushed higher by a patent update. investorplace.com - 3 months ago
Why Is Tivic Health Systems (TIVC) Stock Up 44% Today? Tivic Health Systems (NASDAQ: TIVC ) stock is rising higher on Thursday after the bioelectronic medicine company updated its intellectual property portfolio. According to Tivic Health Systems, it has received two new patents that better protect its intellectual properties. investorplace.com - 3 months ago
Tivic Health: Christina Valauri Appointed to Board of Directors SAN FRANCISCO--(BUSINESS WIRE)--Tivic Health® Systems, Inc. (“Tivic Health”, Nasdaq: TIVC), a health tech company that develops and commercializes bioelectronic medicine, is pleased to welcome Christina Valauri to its board of directors, effective July 1, 2024. Ms. Valauri has served as a strategic advisor to the company since April 2023, and brings over 30-years of experience as a seasoned capital markets professional with extensive analytical and management experience. Ms. Valauri has a prove. businesswire.com - 4 months ago
8. Profile Summary

Tivic Health Systems, Inc. TIVC

image
COUNTRY US
INDUSTRY Medical - Devices
MARKET CAP $ 1.79 M
Dividend Yield 0.00%
Description Tivic Health Systems Inc. operates as a bioelectronic device company that delivers non-invasive neuromodulation products for the treatment of inflammatory conditions. Its primary product is ClearUP, is a medical device intended to relieve sinus and nasal inflammation. The company sells its products on direct-to-consumer channel through its own websites; and platforms, such as Amazon.com and Walmart.com, as well as to U.S. online retailers, including BestBuy.com and FSAStore.com. Tivic Health Systems, Inc. was incorporated in 2016 and is headquartered in Hayward, California.
Contact 25821 Industrial Boulevard, Hayward, CA, 94545 https://www.tivichealth.com
IPO Date Nov. 11, 2021
Employees 9
Officers Dr. Blake Gurfein Ph.D. Chief Scientific Officer Ms. Lisa G. Wolf Interim Chief Financial Officer Ms. Jennifer Ernst Co-Founder, Chief Executive Officer & Director